S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Treace Medical Concepts Stock Forecast, Price & News

+0.22 (+0.76 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume96,800 shs
Average Volume235,236 shs
Market Capitalization$1.55 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TMCI News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

About Treace Medical Concepts

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.60 out of 5 stars

Medical Sector

982nd out of 1,352 stocks

Surgical & Medical Instruments Industry

98th out of 123 stocks

Analyst Opinion: 2.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Treace Medical Concepts (NASDAQ:TMCI) Frequently Asked Questions

Is Treace Medical Concepts a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Treace Medical Concepts stock.
View analyst ratings for Treace Medical Concepts
or view top-rated stocks.

What stocks does MarketBeat like better than Treace Medical Concepts?

Wall Street analysts have given Treace Medical Concepts a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Treace Medical Concepts wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Treace Medical Concepts' next earnings date?

Treace Medical Concepts is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Treace Medical Concepts

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced its quarterly earnings results on Thursday, August, 5th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.02. The business had revenue of $20.65 million for the quarter, compared to the consensus estimate of $18.80 million.
View Treace Medical Concepts' earnings history

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $90 million-$95 million, compared to the consensus revenue estimate of $90.07 million.

What price target have analysts set for TMCI?

4 brokers have issued 12-month price targets for Treace Medical Concepts' stock. Their forecasts range from $32.00 to $38.00. On average, they anticipate Treace Medical Concepts' share price to reach $35.50 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price.
View analysts' price targets for Treace Medical Concepts
or view top-rated stocks among Wall Street analysts.

Who are Treace Medical Concepts' key executives?

Treace Medical Concepts' management team includes the following people:
  • Mr. John T. Treace, CEO, Founder & Director (Age 49)
  • Mr. Thomas E. Timbie, Independent Director (Age 63)
  • Mr. Mark L. Hair, Chief Financial Officer (Age 51)
  • Mr. Jaime A. Frias, Chief Legal & Compliance Officer and Sec. (Age 59)
  • Dr. Sean F. Scanlan Ph.D., Sr. VP of Marketing & Medical Education (Age 39)
  • Mr. Dipak A. Rajhansa, Sr. VP of Sales (Age 51)
  • Mr. Daniel E. Owens, Chief HR Officer (Age 49)
  • Mr. Joe W. Ferguson, Sr. VP of R&D (Age 52)
  • Ms. Shana Zink, Sr. VP of Clinical Affairs & Reimbursement
  • Ms. Rachel Osbeck, Sr. VP of Quality Assurance & Regulatory Affairs

When did Treace Medical Concepts IPO?

(TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

What is Treace Medical Concepts' stock symbol?

Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI."

When does the company's lock-up period expire?

Treace Medical Concepts' lock-up period expires on Wednesday, October 20th. Treace Medical Concepts had issued 11,250,000 shares in its initial public offering on April 23rd. The total size of the offering was $191,250,000 based on an initial share price of $17.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by a number of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (2.34%), Perceptive Advisors LLC (2.34%), Next Century Growth Investors LLC (2.49%), Vanguard Group Inc. (2.40%), Kayne Anderson Rudnick Investment Management LLC (1.93%) and BlackRock Inc. (1.71%). Company insiders that own Treace Medical Concepts stock include Jaime A Frias, John R Treace, John T Treace and Mark Hair.
View institutional ownership trends for Treace Medical Concepts

Which major investors are buying Treace Medical Concepts stock?

TMCI stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Next Century Growth Investors LLC, Vanguard Group Inc., Kayne Anderson Rudnick Investment Management LLC, BlackRock Inc., FMR LLC, and Jennison Associates LLC.
View insider buying and selling activity for Treace Medical Concepts
or or view top insider-buying stocks.

How do I buy shares of Treace Medical Concepts?

Shares of TMCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Treace Medical Concepts' stock price today?

One share of TMCI stock can currently be purchased for approximately $29.35.

How much money does Treace Medical Concepts make?

Treace Medical Concepts has a market capitalization of $1.55 billion.

How many employees does Treace Medical Concepts have?

Treace Medical Concepts employs 133 workers across the globe.

What is Treace Medical Concepts' official website?

The official website for Treace Medical Concepts is www.treace.com.

Where are Treace Medical Concepts' headquarters?

Treace Medical Concepts is headquartered at 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081.

How can I contact Treace Medical Concepts?

Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The company can be reached via phone at 904-373-5940 or via email at [email protected].

This page was last updated on 9/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.